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Abstract
A recent genomewide association study reported association between schizophrenia and the
ZNF804A gene on chromosome 2q32.1. We attempted to replicate these findings in our Irish Case-
Control Study of Schizophrenia (ICCSS) sample (N=1021 cases, 626 controls). Following
consultation with the original investigators we genotyped 3 of the most promising SNPs from the
Cardiff study. We replicate association with rs1344706 (trend test one tailed p=0.0113 with the
previously associated A allele) in ZNF804A. We detect no evidence of association with rs6490121
in NOS1 (one tailed p=0.21), and only a trend with rs9922369 in RGRIP1L (one tailed p=0.0515).
Based on these results, we completed genotyping of 11 additional LD-tagging SNPs in ZNF804A.
Of 12 SNPs genotyped, 11 pass QC criteria and 4 are nominally associated, with our most significant
evidence of association at rs7597593 (p=0.0013) followed by rs1344706. We observe no evidence
of differential association in ZNF804A based on family history or sex of case. The associated SNP
rs1344706 lies in ~30 bp of conserved mammalian sequence and the associated A allele is predicted
to maintain binding sites for the brain-expressed transcription factors MYT1L and POU3F1/OCT-6.
In controls, expression is significantly increased from the A allele of rs1344706 compared to the C
allele. Expression is increased in schizophrenic cases compared to controls, but this difference does
not achieve statistical significance. This study replicates the original reported association of
ZNF804A with schizophrenia and suggests that there is a consistent link between the the A allele of
rs1344706, increased expression of ZNF804A and risk for schizophrenia.
INTRODUCTION
Schizophrenia (MIM 181500) is a severe psychiatric illness with complex etiology and lifetime
prevalence of ~1% worldwide. Family, twin and adoption studies have consistently
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demonstrated an important genetic component to schizophrenia, together with developmental
and environmental influences1,2.
The genomewide association study (GWAS), with up to 1 million single nucleotide
polymorphisms (SNPs) genotyped, is currently the most powerful, systematic and unbiased
genetic approach to the study of the common disease/common variant (CDCV) hypothesis of
complex disorders like schizophrenia. Since the initial suggestion by Risch and Merikangas of
the power of association methods for human diseases3, GWAS have successfully identified
novel associations and/or replicated prior susceptibility genes for a number of complex traits,
including age-related macular degeneration4, Type 15 and Type 26–11 diabetes, episodic
memory12, Crohn’s disease13–16, prostate cancer17–19 and obesity20.
So far, 3 independent schizophrenia GWAS using individual genotyping have been
published21–23. Sample sizes (and power) are modest given the range of effect sizes and allele
frequencies expected. These studies have not provided either convergence between new loci
identified or strong support for loci previously identified (for example, through positional
cloning). Direct replication studies of current GWAS findings have provided mixed results.
The first of these used a sample of 178 cases and 144 controls, assessed 500K SNPs and reported
one experiment-wide significant association at rs4129148 (P= 3.7×10−7) in the X/Y
pseudoautosomal region near the CSF2RA and IL3R genes21. Cytokines have been suggested
as possible candidate genes previously, and one replication attempt supported association in
IL3R24. The second used the CATIE25 sample of 738 cases and 733 controls and reported no
genomewide significant results in stage 1 analysis22. The third used a multi-stage design of
discovery in a newly genotyped sample of 479 cases compared with existing data from the
2937 UK controls used in the Wellcome Trust Case/Control Consortium studies26 and targeted
replication in 6666 cases and 9897 controls. This study reported consistent evidence of
association with 1 SNP in the zinc-finger protein ZNF804A gene23. Although the discovery
sample in this study was modest, it is drawn from an Anglo-Celtic population (from Wales and
the UK) broadly similar to the population from which we have sampled cases and controls
(from Ireland and Northern Ireland) and the total sample size was substantial due to the use of
existing control data. We therefore set out to replicate the findings from the Cardiff study in
our Irish case/control sample.
MATERIALS, METHODS AND SAMPLES
The Irish Case/Control Study of Schizophrenia (ICCSS) Sample
Cases were ascertained from in-patient and out-patient psychiatric facilities in Ireland and
Northern Ireland. Cases completed the same diagnostic instrument used in our prior family
study, the Structured Clinical Interview for DSM III-R, Patient version with an expanded
psychosis section27; DSM-III-R criteria were used for consistency with our family
collection28. Detailed personal interviews and hospital record rating forms were completed for
each proband. Subjects with a field diagnosis of schizophrenia or poor-outcome schizoaffective
disorder were eligible if all four grandparents were born in Ireland or the UK. The ICCSS
sample includes 1021 cases.
Controls (N=626) were recruited from donors at the Northern Ireland Blood Transfusion
Service (N=554) and from the Irish national police (N=38) and army reserve (N=34). Controls
were briefly screened and were eligible if they reported no history of schizophrenia and all
four grandparents born in Ireland or the UK. All participants gave appropriate informed
consent. Recorded sex was verified by X/Y genotypes; cases were 68% male and 32% female,
controls were 55% male, 45% female. This sample has ≥78% power to detect effects with
minor allele frequency (MAF) ≥20% and allelic odds ratio (OR) ≥1.3.
Riley et al. Page 2
Mol Psychiatry. Author manuscript; available in PMC 2010 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Ireland is relatively isolated at the North Western extreme of Europe, which may be
advantageous in investigating a complex genetic disorder such as schizophrenia. The current
Irish population, though not a genetic isolate, is more homogeneous than the US
population29–31. Fewer ancestral haplotypes increase LD and the power to detect association.
Studies of Y chromosome and mtDNA point to a common genetic legacy in Ireland that
probably extends back to the repopulation of the island, after the last Ice Age approximately
15,000 years ago, from population centres in the Iberian peninsula and south western
France32–34. The genetic structure of the population has been minimally influenced by more
recent human migrations over the last three millennia34. In the experience of the blood bank
staff, non-Irish donors are very rare, in agreement with the history of minimal in-migration to
Ireland, and would have been excluded on the basis of questions about their grandparents.
Family History
Family history research diagnostic criteria (FH-RDC)35 were assessed by having affected
participants complete the FH-RDC interview36, the best validated instrument available, to
report on psychotic illness in relatives. Detailed study of the reliability, sensitivity and
specificity of the FH-RDC versus personal interview of first-degree family members in the
Roscommon Family Study37 showed that between informants, the kappa±SE was 0.49±0.02;
between FH-RDC and best-estimate diagnoses, the kappa±SE was 0.43±0.02. Validated
against the best-estimate diagnosis (which included personal interview and hospital records in
most cases), the sensitivity was 0.37 and the specificity was 0.996. The FH-RDC criteria38 and
instrument36 thus miss true illness in relatives but almost never produce a false positive.
Family history information is available for 739 cases (72.4%). We defined positive family
history (FH+) by report of 1 or more first-degree relatives with schizophrenia or unspecified
functional psychosis. We restrict the definition to first-degree relatives because we expect
greater reliability of reporting for immediate family members. Unspecified functional
psychosis required positive report of one or more specific symptoms (delusions, hallucinations,
incoherence, or bizarre behavior) not due to a mood disorder. Under this definition, there are
196 FH+ cases. We compare these to the most conservatively defined 478 FH− cases reporting
no psychotic illness in either first or second degree relatives. This approach has ≥65% power
to detect differences between the FH+ and FH− subsamples assuming the same parameters as
in our case/control power calculation (MAF ≥20%, allelic OR ≥1.3 and alpha=0.05).
Marker Selection and Genotyping
Following discussion with the Cardiff group, we genotyped 3 of the most promising SNPs
from the report of genomewide association in the Cardiff sample, rs1344706 in ZNF804A,
rs6490121 in NOS1 and rs9922369 in RGRIP1L. Based on the results in these markers, we
then completed genotyping of 11 additional LD-tagging SNPs (tSNPs) in ZNF804A. We first
manually included rs1344706 (associated in the original study) in the test alleles set and then
selected additional tSNPs using the TAGGER39 algorithm with default criteria of r2≥0.8 and
minor allele frequency (MAF)≥0.2 as implemented in Haploview 4.040 using HapMap data
release 22/Phase II, Apr 07. Including rs1344706, we genotyped a total of 12 SNPs in
ZNF804A. Markers are shown in Table 1; orientation and alleles are reported on the genomic
(+) strand (rs1344706 is reported here as A/C, not T/G as in the original report23).
All markers were genotyped with Taqman Assays-on-Demand (Applied Biosystems, Foster
City, CA). To ensure uniformity and accuracy, all reaction steps were performed using the
Eppendorf 5075 automated liquid handling platform. Genotypes were called using an
automated allele scoring platform41. For quality control, we exclude any individual with >50%
missing genotypes. We analyzed duplicate genotype data for 35 duplicate pairs (11 cases and
24 controls) and use discordant genotypes in these duplicates to estimate genotyping error rates.
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Statistical Analysis
Primary Analyses—Single marker analyses were performed in SAS42 and followed the
original study in assessing the Cochran-Armitage trend test. For GWAS data, the trend test is
widely thought to be the most robust and broadly appropriate primary hypothesis test currently
available and here it also provides the closest possible test of replication. Previous work
demonstrated 1) validity of the trend statistic in the presence of Hardy Weinberg
disequilibrium, and 2) asymptotic equivalence of allele and genotype-based trend statistics
when Hardy Weinberg equilibrium holds43. We present uncorrected results from one-tailed
tests of the three direct replication SNPs (rs1344706 in ZNF804A, rs6490121 in NOS1 and
rs9922369 in RGRIP1L). We treat the remaining analyzed SNPs in ZNF804A (10 after one
SNP dropped during QC) as independent (based on their selection as tags) and apply Bonferroni
correction for 10 tests.
Haplotype analyses were performed assessing Χ2 in Haploview v4.040. The Χ2 is also
appropriate given the ethnic homogeneity of our sample and the absence of observed
substructure in the Irish population44. We also use HAPLOVIEW to identify significant
(p<0.001) departures from Hardy-Weinberg Equilibrium (HWE) and compare linkage
disequilibrium (LD) against HapMap data. Haplotypes were analyzed within blocks defined
by the default confidence-interval method45. In one additional analysis undertaken on the basis
of single marker association results, we analyzed rs7597593 (not included in any confidence-
interval defined block) with the confidence-interval defined SNP set that includes rs1344706.
We assessed empirical significance of haplotype results with 5000 permutations of case and
control status.
Secondary Analyses—To assess potential gender differences in the association signal, we
tested for SNP × Sex interaction using logistic regression, coding each SNP in an additive
framework, including gender and a SNP × Sex interaction term. To test for differences in
evidence for association between sets of cases defined by FH status, we stratified the sample
by the presence (FH+) or absence (FH−) of first degree relatives with schizophrenia or
unspecified psychosis as described above (1st degree broad definition). Genotypes at
rs1344706 were missing for 23 individuals with FH data, and We tested for allelic (1df)
association by assessing Χ2 between FH+ and FH− cases. Both analyses were performed using
SAS42.
Gene Expression Analysis
Post-mortem Brain Tissue Samples—The Stanley Medical Research Institute (SMRI)
provided genomic DNA and postmortem brain tissue samples from dorsolateral prefrontal
cortex (Brodmann’s area 46) from 35 individuals with schizophrenia (SCH) and 35 controls
(CON). Exclusion criteria for these samples included: (1) significant structural brain pathology,
(2) history of pre-existing central nervous system disease, (3) poor RNA quality, (4)
documented IQ < 70, (5) age less than 30 and (6) substance abuse within one year of death46.
RNA was isolated using the Ambion miRvana kit (Applied Biosystems, Foster City, CA)
according to manufacturer’s instructions. We obtained poor yields of RNA from 1 CON
sample, which was excluded from further study, leaving 35 SCH and 34 CON samples.
Quantitative Real-Time PCR—cDNA was reverse transcribed using the Ready-To-Go Kit
from Amersham Bioscience (Piscataway, NJ) following manufacturer’s instructions.
ZNF804A expression was analyzed on the StepOne Plus instrument (ABI, Foster City, CA)
using a Taqman quantitative real-time PCR expression assay (ABI, Foster City, CA). Each
sample was assayed in triplicate and mean values from the triplicates were used for all analyses.
Gene expression was normalized against two reference genes47 (HPRT and TBP), and analyzed
by the 2−ΔΔCT algorithm48. The 2−ΔΔCT algorithm, widely used to compare differences in gene
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expression, is valid only if PCR efficiency of studied genes is equal48. PCR efficiencies
(measured by standard curve) of all three genes assayed were very similar (ZNF804A: 91%,
HPRT: 93%, TBP: 90%).
Statistical Analysis of Expression Data—To achieve a normal distribution, ZNF804A
expression values were log transformed, and normality of the transformed data was verified
by the Anderson-Darling empirical distribution function test49,50, a powerful statistic to detect
departure from normality even in a relatively small (N≤100) sample. Samples (N=7, 3 SCH
and 4 CON) with values greater than ±2SD from the group mean were omitted from further
analyses, reducing the totals to 32 SCH and 30 CON. Mean expression levels in SCH and CON
groups were compared using Welch’s corrected unpaired t-test. The potential confounding
effects of diagnosis, age, gender, pH, post-mortem interval, refrigerator interval, smoking and
drug abuse in the analysis of ZNF804A expression were assessed by analysis of variance
(ANOVA).
Statistical Analysis of Expression by rs1344706 Genotype—We assessed sequence
around SNP rs1344706 in the UCSC Genome Browser (http://genome.ucsc.edu). Based on
evidence of conservation, we sought to identify transcription-factor bindingsites altered by the
alternative rs1344706 alleles. A 53 bp sequencesurrounding rs1344706
(chr2:185,486,646-185,486,698) was analyzed using MatInspector v7.7.3.1 and SNPinspector
v2.251 (http://www.genomatix.de/). In both cases the vertebrate transcription factor matrices
and optimized matrix threshold were used to reduce the incidence of false-positives.
Based on the results of these predictions, the SMRI CON samples were genotyped for
rs1344706 for analysis of expression differences due to variation at this position. Genotypes
are collected exactly as described above using the same instrumentation and reagents.
For the allelic test, expression values were binned by rs1344706 allele and the means of the
bins were then compared52. Each individual’s expression value is used twice: for homozygotes,
twice in the same bin, for heterozygotes, once in each. As a result, the variation in the
homozygotes may be less than that in heterozygotes, and we therefore compare the two group
means using the unpaired t-test with Welch’s correction to account for possible heteroscedastic
variances.
RESULTS
Genotyping: Missingness, Error Rates and LD
A total of 28 case (2.7%) and 56 (8.9%) control samples were excluded from analysis with
>50% missing genotypes. All subsequent results are based on a total of 1563 samples (993
cases and 570 controls). Of these, 1499 (95.9%) are missing 2 or fewer genotypes (1270
samples (81.3%) missing zero, 195 (12.5%) missing one and 36 (2.3%) missing two
genotypes). Higher missing data rates (3–7 genotypes) were present in 62 samples (4.0%).
The rates of sample exclusion due to missing genotypes are higher than usual due to technical
issues during genotypic data collection. Degradation of a filter in a fluorescence reader reduced
signal at the detector, thus artificially increasing the minimum signal necessary for detection.
This attenuation of signal did not affect robustly performing samples, but did cause a higher
fail rate among more weakly amplifying samples. Prior to exclusion of poorly genotyped
samples, average genotyping completion by marker was 93.5% (90.5–96.4%); following
exclusions, it was 97.3% (95.2–99.2%). Following identification of the problem and
replacement of the filter, 4 SNPs (rs13393273, rs7597593, rs1344706 and rs4667001,
including the two most strongly associated) were completely regenotyped. This repeated data
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collection yields a higher genotyping completion rate (mean 98.5%) and a low rate (0.52%) of
discordant genotypes for these four markers.
We genotyped 14 SNPs × 35 samples in duplicate (N=490 genotype pairs); both genotypes
were available for 465 (94.9%), of which 0 were discordant, estimating our overall genotyping
error rate at less than 1 in 465 (<0.21%). All markers except rs1480481 (p=1.13×10−10 and
not further analyzed) satisfied our HWE cut-off for inclusion. Linkage disequilibrium patterns
in this sample are virtually identical to those in HapMap data (Figure S1).
Single Marker Analysis
ZNF804A—Results of single marker analyses are shown in Table 1. In the data from
ZNF804A, rs1344706 (associated in the original report in discovery and combined replication
samples) is also associated in the ICCSS (one-tailed p=0.0113). The same allele (A) is increased
in frequency in cases compared to controls as in the original study. In total, we observe nominal
evidence of association between schizophrenia and 4 of the 11 SNPs passing QC criteria. The
T allele of rs7597593 yields substantially more significant evidence of association (two-tailed
p=0.0013), but this SNP lacks the evidence of possible functional significance observed for
rs1344706 (see below). The single marker results from rs7597593 (p=0.0013) remain
significant after Bonferroni correction for 10 tests. Allele and genotype counts are shown in
Table S1.
NOS1 and RGRIP1L—No significant difference between cases and controls was observed
for rs6490121 in NOS1. Results for rs9922369 in RGRIP1L show only a trend towards
significance (one-tailed p=0.0515), with the same allele as originally reported observed to be
more common in cases in our study. Allele and genotype counts are shown in Table S1.
Haplotype Analysis
Results of haplotype analyses within confidence interval defined blocks are shown in Table 2.
Compared to single marker analyses, we observe an increased association in block 3
(containing rs1344706) on a haplotype (frequency 0.188 in controls) bearing the common
alleles of rs7605689 (T) and rs3931790 (T), the rare allele of rs7603001 (A) and the previously
associated common (A) allele of rs1344706 (Χ2= 8.626, p<0.003). The increased significance
is due to a larger case/control difference (5%) in the frequency of this TTAA haplotype
compared to the difference for the A allele of rs1344706 (4%).
In a single targeted secondary haplotype analysis, we included the associated SNP rs7597593
with the 4 markers in the confidence interval defined block 3, containing rs1344706. We
observe a further increase in association for the haplotype defined by the associated allele of
rs7597593 (T) in conjunction with the TTAA haplotype associated above. This comparison
provides the largest observed haplotypic frequency difference between cases and controls
(5.2%), and is the only haplotypic comparison to remain significant after permutation testing
(P=0.017).
SNP × Sex Interaction Analysis
In logistic regression tests of SNP × Sex interaction (Table S2), 8 markers in ZNF804A yield
nominally significant evidence of association including all 4 that were associated in primary
analyses (rs17508595, rs13393273, rs7597593 and rs1344706). The SNP × Sex interaction
term was not significant for any marker tested, providing no evidence for differential
association depending on the sex of the case.
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Family History Analysis
Based on the single marker results above, we limited FH analyses to the most significantly
associated markers, rs7597593 and rs1344706 (Table S3). Using the categorical definitions
described in Methods, there are 196 FH+ and 478 conservatively defined FH− cases (no illness
reported in first or second degree family members) in the ICCSS sample. A genotype at
rs1344706 was missing for 23 individuals with family history (15 FH− and 8 FH+), leaving a
total analyzed sample N=651 (1302 alleles), 463 FH− and 188 FH+. There is no evidence of
any difference in association of rs1344706 and rs7597593 between FH+ and FH− cases (Table
S3).
Expression analysis
We assessed gene expression differences for ZNF804A in RNA from the prefrontal cortex from
the SMRI SCH and CON samples. We excluded 3 SCH and 4 CON outlier samples, as
described above, leaving 32 SCH and 30 CON for analysis. Expression was higher in SCH
compared to CON samples, but this difference did not achieve statistical significance (Welch-
corrected t=1.640, df=52, p=0.107, Figure 1A).
Bioinformatic Analysis of rs1344706
Inspection of the sequence around SNP rs1344706 shows that it lies in a short region of
conserved mammalian sequence in intron 2 of ZNF804A. MatInspector results for the 53 bp
of sequence we assessed (chr2:185,486,646-185,486,698) include the A allele of rs1344706
in the predicted binding sites for two brain-expressed transcription factors, Myt1L53,54 and
POU3F1/Oct-655, both implicated in multiple CNS developmental processes, particularly in
oligodendrocytes54,55. Two additional binding sites are predicted in the presence of the C allele.
One of these is for the ubiquitously expressed Homez56 and the other is for Hmx2, which,
while expressed in the CNS, is thought to be primarily involved in the development of the inner
ear57–59 (Figure S2).
Genotype-specific expression
The SMRI postmortem CON samples were genotyped for rs1344706. Allele frequencies in the
N=30 CON samples were A: 32/60, 0.533; C: 28/60, 0.477, and were in good agreement with
data from the HapMap (A: 0.567; C: 0.433) and Irish (A: 0.607; C: 0.393) samples. Expression
is significantly higher for the associated A allele (t=2.129, df=39, p=0.033, Figure 1B). The
observed difference was not due to effects of potential confounder variables assessed by
ANOVA (age, post-mortem interval, refrigeration interval, brain pH or smoking, F=0.829;
df=12; p=0.62).
DISCUSSION
We studied ZNF804A in a case/control sample appropriate for replication of the original results.
First, our sample was drawn from Ireland and should have substantial genetic overlap with the
Anglo-Celtic discovery sample. Second, our ascertainment and diagnosis methods were highly
homologous with those used to collect the discovery sample. Third, the ICCSS sample has
substantial power to detect genetic effects.
Our study provides further support for the association of schizophrenia with common variant
alleles and haplotypes in ZNF804A. We replicate the previously reported observation of genetic
association between schizophrenia and the A allele of rs1344706. In an extended set of tSNPs,
we also observe association with the minor T allele of rs7597593, with a haplotype containing
the A allele of rs1344706, and with a haplotype containing the A allele of rs1344706 and the
T allele of rs7597593. Only the single marker results from rs7597593 remain significant after
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Bonferroni correction, and only the results from the longer haplotype including rs7597593
remain significant after permutation testing. LD and haplotypes agree closely with prior
observations in other European-descended samples. There is no evidence for differential
association with ZNF804A between male and female cases or between cases with and without
a positive family history of schizophrenia-like illness.
Although it seems unlikely that SNP rs1344706 directly increases risk for schizophrenia, the
association and expression data collectively are consistent with possible functional effects at
rs1344706 itself. The A allele shows significantly higher expression than the C allele in control
dorsolateral prefrontal cortex. The A allele is associated with schizophrenia, and expression in
schizophrenic case dorsolateral prefrontal cortex is increased relative to that in controls,
although this last difference does not achieve statistical significance.
Bioinformatic analysis of the source of the mammalian conservation around rs1344706
suggests it may be due to the presence of transcription factor binding sites. The alleles of
rs1344706 result in differential prediction of the presence of binding sites for two brain-
expressed transcription factors. The Myt1L zinc finger protein is expressed in neural
progenitors along with the related family member Myt1 (which is known to modulate
proliferation and terminal differentiation of oligodendrocyte progenitors54.) Of note, the
MYT1L gene was included in a copy number variant observed in an affected individual in a
recent study of structural variation in schizophrenia. The POU3F1/Oct-6 POU-domain
transcription factor is involved in oligodendrocyte differentiation55 and the transition of pro-
myelinating to myelinating Schwann cells60, and is also normally expressed in adult cortex
and hippocampus61. Those transcription factors predicted to bind to the C allele of rs1344706
are widely expressed and not brain-specific (Homez) or involved primarily in the development
of the inner ear, and so seem potentially less meaningful in this context.
The pattern of association in published GWAS findings for schizophrenia (and particularly
their replication) has been highly variable. Although these studies have shown little support
for the results of either other GWAS or prior studies, sample sizes in many cases have not been
adequate to deliver reasonable power. In this case, although the discovery sample was
somewhat small, the replication sample has reasonable power to detect effects in the ranges
modeled. Additional results from a number of large, better powered studies and from meta-
analyses of more than 10,000 cases and controls (which have substantial power to detect effects
of the kind expected in schizophrenia) are expected in the near future. These results will be
critical in determining which of the early results are widely supported. In conclusion, however,
our results from the present study of ZNF804A and schizophrenia in a large, ethnically
homogeneous sample add further support for the association of the A allele at rs1344706 with
schizophrenia.
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Figure 1.
ZNF804A gene expression in the SMRI sample. A. Comparison of ZNF804A expression in
schizophrenic (SCH) and control (CON) samples.
B. ZNF804A expression in SMRI control samples stratified by rs1344706 allele.
Riley et al. Page 12
Mol Psychiatry. Author manuscript; available in PMC 2010 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Ta
bl
e 
1
R
es
ul
ts
 o
f s
in
gl
e 
m
ar
ke
r 
an
al
ys
es
 fo
r 
SN
Ps
 in
 Z
N
F8
04
A,
 N
O
S1
 a
nd
 R
G
RI
P1
L
2-
ta
ile
d 
p-
va
lu
es
 a
re
 sh
ow
n 
fo
r a
ll 
te
st
s a
nd
 1
-ta
ile
d 
p-
va
lu
es
 a
re
 sh
ow
n 
fo
r t
he
 th
re
e 
pr
ev
io
us
ly
 re
po
rte
d 
SN
Ps
L
oc
us
M
bp
SN
P
A
lle
le
f C
as
es
f C
on
tr
ol
s
A
lle
lic
 O
R
 (9
5%
 C
I)
C
A
 (Z
)
1t
 p
2t
 p
H
W
E
 p
C
hr
 2
 Z
N
F8
04
A
18
5.
19
rs
13
39
32
73
G
0.
44
0.
4
1.
17
 (1
.0
1–
1.
36
)
−2
.1
07
0.
03
51
0.
26
84
18
5.
19
rs
17
50
85
95
G
0.
31
0.
27
1.
21
 (1
.0
2 
− 1
.4
3)
−2
.2
85
0.
02
30
0.
08
09
18
5.
20
rs
12
61
31
95
C
0.
7
0.
67
1.
15
 (0
.9
8 
− 1
.3
5)
−1
.6
87
0.
09
17
0.
72
66
18
5.
22
rs
12
69
33
85
T
0.
57
0.
54
1.
11
 (0
.9
6 
− 1
.2
9)
−1
.4
21
0.
15
53
0.
51
29
18
5.
24
rs
75
97
59
3
T
0.
44
0.
38
1.
28
 (1
.1
0 
− 1
.4
9)
−3
.2
12
0.
00
13
0.
86
47
18
5.
26
rs
14
80
48
1
C
0.
41
0.
35
1.
13
E-
10
18
5.
41
rs
76
05
68
9
T
0.
81
0.
79
1.
12
 (0
.9
3 
− 1
.3
5)
−1
.2
22
0.
22
16
0.
47
75
18
5.
47
rs
39
31
79
0
T
0.
83
0.
81
1.
10
 (0
.9
1 
− 1
.3
4)
−0
.9
98
0.
31
81
0.
88
94
18
5.
48
rs
76
03
00
1
A
0.
51
0.
47
1.
16
 (1
.0
0 
− 1
.3
4)
−1
.9
29
0.
05
37
0.
72
86
18
5.
49
rs
13
44
70
6
A
 (+
)
0.
65
0.
61
1.
20
 (1
.0
3 
− 1
.4
0)
−2
.2
79
0.
01
13
0.
02
27
0.
01
53
18
5.
51
rs
46
67
00
1
G
0.
44
0.
41
1.
14
 (0
.9
8 
− 1
.3
2)
−1
.6
61
0.
09
66
0.
60
28
18
5.
51
rs
12
47
74
30
A
0.
33
0.
29
1.
17
 (1
.0
0 
− 1
.3
8)
−1
.9
09
0.
05
63
0.
76
32
M
bp
SN
P
A
lle
le
f C
as
es
f C
on
tro
ls
A
lle
lic
 O
R
 (9
5%
 C
I)
C
A
 (Z
)
1t
 p
2t
 p
H
W
E
 p
C
hr
 1
2 
N
O
S1
11
6.
19
rs
64
90
12
1
A
0.
66
0.
65
1.
07
 (0
.9
1 
− 1
.2
5)
−0
.8
06
0.
21
0
0.
42
0
0.
75
91
M
bp
SN
P
A
lle
le
f C
as
es
f C
on
tro
ls
A
lle
lic
 O
R
 (9
5%
 C
I)
C
A
 (Z
)
1t
 p
2t
 p
H
W
E
 p
C
hr
 1
6 
RG
RI
P1
L
52
.2
1
rs
99
22
36
9
A
 (+
)
0.
03
0.
02
1.
57
 (0
.9
1 
− 2
.7
1)
−1
.6
31
0.
05
15
0.
10
29
1
N
ot
e 
th
at
 rs
13
44
70
6 
is
 h
er
e 
re
po
rte
d 
on
 th
e 
ge
no
m
ic
 (+
) s
tra
nd
, w
he
re
 it
s a
lle
le
s a
re
 A
 o
r C
. A
ss
oc
ia
te
d 
SN
Ps
 a
re
 sh
ow
n 
in
 b
ol
d,
 (+
) i
nd
ic
at
es
 th
e 
sa
m
e 
al
le
le
 a
s o
bs
er
ve
d 
in
 th
e 
or
ig
in
al
 st
ud
y.
 M
bp
: p
hy
si
ca
l
po
si
tio
n 
in
 m
eg
ab
as
ep
ai
rs
; f
C
as
es
/C
on
tro
ls
: F
re
qu
en
cy
 o
f i
nd
ic
at
ed
 al
le
le
 in
 ca
se
s a
nd
 co
nt
ro
ls
 re
sp
ec
tiv
el
y;
 C
A
 (Z
): 
C
oc
hr
an
-A
rm
ita
ge
 te
st
 st
at
is
tic
; 1
t p
, 2
t p
: o
ne
- a
nd
 tw
o-
ta
ile
d 
p-
va
lu
es
 re
sp
ec
tiv
el
y;
 H
W
E
p:
 H
ar
dy
-W
ei
nb
er
g 
eq
ui
lib
riu
m
 p
-v
al
ue
.
Riley et al. Page 13
Mol Psychiatry. Author manuscript; available in PMC 2010 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Ta
bl
e 
2
R
es
ul
ts
 o
f h
ap
lo
ty
pe
 a
na
ly
se
s f
or
 S
N
Ps
 in
 Z
N
F8
04
A
A
ss
oc
ia
te
d 
ha
pl
ot
yp
es
 a
re
 sh
ow
n 
in
 b
ol
d.
B
lo
ck
H
T
Fr
eq
.
f C
as
es
f C
on
tr
ol
s
C
hi
 S
q
p
P
B
lo
ck
 1
A
C
0.
57
7
0.
56
4
0.
60
1
3.
93
5
0.
04
73
0.
55
8
G
G
0.
28
8
0.
30
2
0.
26
3
5.
53
1
0.
01
87
0.
28
4
G
C
0.
13
5
0.
13
4
0.
13
7
0.
06
2
0.
80
33
1
B
lo
ck
 2
C
T
0.
55
7
0.
56
7
0.
54
1
1.
95
6
0.
16
19
0.
95
2
G
C
0.
31
2
0.
30
1
0.
33
2
3.
23
8
0.
07
2
0.
72
1
C
C
0.
13
0.
13
2
0.
12
7
0.
17
1
0.
67
96
1
B
lo
ck
 3
T
T
A
A
0.
30
4
0.
32
2
0.
27
2
8.
62
6
0.
00
33
0.
05
8
C
TA
A
0.
19
4
0.
18
7
0.
20
7
1.
82
2
0.
17
71
0.
96
4
TT
G
C
0.
19
1
0.
18
0.
20
9
3.
67
4
0.
05
53
0.
61
1
TG
G
C
0.
17
7
0.
17
2
0.
18
4
0.
68
0.
40
94
1
TT
G
A
0.
13
3
0.
13
7
0.
12
6
0.
75
3
0.
38
56
1
rs
75
97
59
3 
+
B
lo
ck
 3
T
T
T
A
A
0.
22
1
0.
24
0.
18
8
11
.2
21
0.
00
08
0.
01
7
C
TT
G
C
0.
18
6
0.
17
5
0.
20
4
4.
01
8
0.
04
5
0.
58
2
C
TG
G
C
0.
17
6
0.
17
1
0.
18
3
0.
62
5
0.
42
93
1
C
C
TA
A
0.
12
0.
11
2
0.
13
4
3.
23
0.
07
23
0.
74
9
TT
TG
A
0.
11
8
0.
12
3
0.
10
9
1.
17
1
0.
27
92
0.
99
8
C
TT
A
A
0.
08
2
0.
08
2
0.
08
1
0.
01
6
0.
89
83
1
TC
TA
A
0.
07
5
0.
07
5
0.
07
6
0.
01
1
0.
91
5
1
C
TT
G
A
0.
01
5
0.
01
5
0.
01
5
0.
00
5
0.
94
19
1
B
lo
ck
 4
A
G
0.
57
0.
55
8
0.
59
2.
95
8
0.
08
55
0.
78
9
G
A
0.
31
5
0.
32
7
0.
29
5
3.
32
9
0.
06
81
0.
69
9
G
G
0.
11
5
0.
11
5
0.
11
5
0
0.
99
01
1
f C
as
es
/C
on
tro
ls
: F
re
qu
en
cy
 o
f i
nd
ic
at
ed
 h
ap
lo
ty
pe
 in
 c
as
es
 a
nd
 c
on
tro
ls
 re
sp
ec
tiv
el
y;
 C
hi
-S
q:
 C
hi
-s
qu
ar
e 
te
st
 st
at
is
tic
; p
 a
nd
 P
: a
sy
m
pt
ot
ic
 a
nd
 e
m
pi
ric
al
 p
er
m
ut
at
io
n 
si
gn
ifi
ca
nc
e 
le
ve
ls
 re
sp
ec
tiv
el
y.
 T
he
un
bl
oc
ke
d,
 a
ss
oc
ia
te
d 
SN
P 
rs
75
97
59
3 
w
as
 in
cl
ud
ed
 in
 a
na
ly
si
s w
ith
 b
lo
ck
 3
 S
N
Ps
 (i
nc
lu
di
ng
 rs
 1
34
47
06
).
Riley et al. Page 14
Mol Psychiatry. Author manuscript; available in PMC 2010 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
